Bio-Techne (TECH) Cash from Financing Activities (2009 - 2026)

Bio-Techne's Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$42.7 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 37.22% year-over-year to -$42.7 million in Q1 2026; TTM through Mar 2026 was -$226.4 million, a 1.26% decrease from a year earlier, with the FY2025 full-year figure at -$253.9 million, down 107.44% from the prior year.
• Cash from Financing Activities rose to -$42.7 million in Q1 2026 per TECH's latest filing, from -$49.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $150.8 million in Q1 2023 and bottomed at -$90.5 million in Q2 2025.
• The 5-year median for Cash from Financing Activities is -$52.4 million (2024), against an average of -$37.6 million.
• Across the five-year window, Cash from Financing Activities soared 324.84% in 2023 and sank 282.02% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$72.2 million in 2022, then retreated by 12.75% to -$81.4 million in 2023, then retreated by 3.0% to -$83.8 million in 2024, then surged by 41.57% to -$49.0 million in 2025, then gained by 12.8% to -$42.7 million in 2026.
• Per Business Quant, the three latest TECH Cash from Financing Activities figures stand at -$42.7 million (Q1 2026), -$49.0 million (Q4 2025), and -$44.2 million (Q3 2025).